Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Gut ; 66(4): 692-704, 2017 04.
Article in English | MEDLINE | ID: mdl-26719303

ABSTRACT

BACKGROUND: The immune contexture predicts prognosis in human colorectal cancer (CRC). Whereas tumour-infiltrating CD8+ T cells and myeloid CD16+ myeloperoxidase (MPO)+ cells are associated with favourable clinical outcome, interleukin (IL)-17-producing cells have been reported to correlate with severe prognosis. However, their phenotypes and functions continue to be debated. OBJECTIVE: To investigate clinical relevance, phenotypes and functional features of CRC-infiltrating, IL-17-producing cells. METHODS: IL-17 staining was performed by immunohistochemistry on a tissue microarray including 1148 CRCs. Phenotypes of IL-17-producing cells were evaluated by flow cytometry on cell suspensions obtained by enzymatic digestion of clinical specimens. Functions of CRC-isolated, IL-17-producing cells were assessed by in vitro and in vivo experiments. RESULTS: IL-17+ infiltrates were not themselves predictive of an unfavourable clinical outcome, but correlated with infiltration by CD8+ T cells and CD16+ MPO+ neutrophils. Ex vivo analysis showed that tumour-infiltrating IL-17+ cells mostly consist of CD4+ T helper 17 (Th17) cells with multifaceted properties. Indeed, owing to IL-17 secretion, CRC-derived Th17 triggered the release of protumorigenic factors by tumour and tumour-associated stroma. However, on the other hand, they favoured recruitment of beneficial neutrophils through IL-8 secretion and, most importantly, they drove highly cytotoxic CCR5+CCR6+CD8+ T cells into tumour tissue, through CCL5 and CCL20 release. Consistent with these findings, the presence of intraepithelial, but not of stromal Th17 cells, positively correlated with improved survival. CONCLUSIONS: Our study shows the dual role played by tumour-infiltrating Th17 in CRC, thus advising caution when developing new IL-17/Th17 targeted treatments.


Subject(s)
Colorectal Neoplasms/immunology , Interleukin-17/metabolism , Lymphocytes, Tumor-Infiltrating/immunology , Th17 Cells/immunology , Th17 Cells/metabolism , Adult , Aged , Aged, 80 and over , CD8-Positive T-Lymphocytes/immunology , Chemokine CCL20/metabolism , Chemokine CCL5/genetics , Chemokine CCL5/metabolism , Chemokine CXCL10/genetics , Chemokine CXCL9/genetics , Colorectal Neoplasms/pathology , Female , HT29 Cells , Humans , Interleukin-17/analysis , Interleukin-17/genetics , Interleukin-8/metabolism , Lymphocytes, Tumor-Infiltrating/chemistry , Male , Middle Aged , Neutrophils/chemistry , Neutrophils/enzymology , Neutrophils/immunology , Peroxidase/analysis , Phenotype , Prognosis , Receptors, IgG/analysis , Survival Rate , T-Lymphocytes, Cytotoxic/immunology , Th17 Cells/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL
...